Drug does not cut heart risk in diabetes patients with CKD, study finds

11/11/2013 | PhysiciansBriefing.com

A Dutch study in the New England Journal of Medicine found bardoxolone methyl was not effective in reducing the odds of cardiovascular death or end-stage renal disease in type 2 diabetes patients with stage 4 chronic kidney disease. Researchers examined 2,185 participants at a median follow-up of nine months and found more patients in the intervention arm were either hospitalized for heart failure or had died of the condition than in the placebo group.

View Full Article in:

PhysiciansBriefing.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC